768397-75-7

Basic information

• Product Name: 3-methylcyclohexanecarbonyl chloride
• Synonyms: 3-methylcyclohexanecarbonyl chloride
• CAS NO: 768397-75-7
• Molecular Weight: 160.644
• Mol File: 768397-75-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-methylcyclohexanecarbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methylcyclohexanecarbonyl chloride(768397-75-7)
• EPA Substance Registry System: 3-methylcyclohexanecarbonyl chloride(768397-75-7)

Safety Data

• Hazardous Substances Data: 768397-75-7(Hazardous Substances Data)

Upstream product

• 13293-59-9 3-methylcyclohexanecarboxylic acid 

Downstream Products

• 1403776-09-9 C₂₀H₂₅N₃O₂ 
• 1403776-22-6 C₁₉H₂₂ClN₃O₂ 
• 13747-97-2 3-methyl-cyclohexanecarboxylic acid amide 

Relevant articles and documents

γ,δ,ε-C(sp3)-H Functionalization through Directed Radical H-Abstraction

Aliphatic amides are selectively functionalized at the γ- and δ-positions through directed radical 1,5 and 1,6 H-abstractions, respectively. The initially formed γ- or δ-lactams are intercepted by N-iodosuccinimide and trimethylsilyl azide, leading to double and triple C-H functionalizations at the γ-, δ-, and ε-positions. This new reactivity is exploited to convert alkyls into amino alcohols and allylic amines.

The second factor as inhibitor XIA pyridonecarboxylic dihydropyridines P1

The present invention provides compounds of Formula (X):(Formula (X), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION NEUROLOGICAL AND PSYCHIATRIC DISORDERS

This invention relates to compounds of formula (I), their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.